Quantitative analysis for AbCellera Biologics Inc. (ABCL) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (55.0) (grade B). 39 signals analyzed (33 differentiated alt-data).
ABCL stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $4.10 | $3.76 | $3.82 |
| 2026-05-11 | $5.63 | $5.24 | $5.25 |
| 2026-05-21 | $5.43 | $4.45 | $5.14 |
| 2026-06-03 | $6.01 | $5.61 | $5.72 |
| 2026-06-15 | $5.55 | $5.17 | $5.26 |
| 2026-06-26 | $7.40 | $6.47 | $7.38 |
| 2026-07-09 | $7.51 | $6.82 | $7.29 |
| 2026-07-21 | $6.05 | $5.54 | $5.97 |
| 2026-07-31 | $5.87 | $5.51 | $5.71 |
| 2026-08-12 | $10.38 | $9.00 | $10.36 |
| 2026-08-24 | $11.01 | $10.44 | $10.61 |
| 2026-09-03 | $11.82 | $11.26 | $11.57 |
How AbCellera Biologics Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| NKTR | Nektar Therapeutics | $1.4B | — |
| DMRA | Galecto, Inc. | $1.5B | — |
| IMCR | Immunocore Holdings plc | $1.5B | — |
| IMTX | Immatics N.V. | $1.5B | — |
View all Health Care stocks by valuation and signals →
AbCellera Biologics Inc. (ABCL) scores Buy (55.0), with no measured dimension below 51. Its highest are analyst consensus at 99, ML forecast at 98, competitive moat at 84, across 6 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 99 |
| ML forecast | 98 |
| competitive moat | 84 |
| valuation | 72 |
| technicals | 53 |
| earnings quality | 51 |
SEC filings show 2 filers (14d) in AbCellera Biologics Inc.. See insider activity methodology for how transaction patterns are analyzed, or view full trading history.
StoQuant analyzes 39 signals (33 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on AbCellera Biologics Inc. (ABCL): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ABCL"><img src="https://stoquant.com/badge/ABCL.svg" alt="AbCellera Biologics Inc. (ABCL) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.